RESUMEN
Variation in individual response to statin therapy has been widely studied for a potential genetic component. Multiple genes have been identified as potential modulators of statin response, but few study findings have replicated. To further examine these associations, 2735 individuals on statin therapy, half on atorvastatin and the other half divided among fluvastatin, lovastatin, pravastatin and simvastatin were genotyped for 43 SNPs in 16 genes that have been implicated in statin response. Associations with low-density lipoprotein cholesterol (LDL-C) lowering, total cholesterol lowering, HDL-C elevation and triglyceride lowering were examined. The only significant associations with LDL-C lowering were found with apoE2 in which carriers of the rare allele who took atorvastatin lowered their LDL-C by 3.5% more than those homozygous for the common allele and with rs2032582 (S893A in ABCB1) in which the two groups of homozygotes differed by 3% in LDL-C lowering. These genetic effects were smaller than those observed with the demographic variables of age and gender. The magnitude of all the differences found is sufficiently small that genetic data from these genes should not influence clinical decisions on statin administration.
Asunto(s)
Ácidos Heptanoicos/uso terapéutico , Hidroximetilglutaril-CoA Reductasas/genética , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Polimorfismo de Nucleótido Simple/genética , Pirroles/uso terapéutico , Anciano , Apolipoproteína E2 , Apolipoproteínas E/genética , Atorvastatina , HDL-Colesterol/efectos de los fármacos , LDL-Colesterol/efectos de los fármacos , Femenino , Frecuencia de los Genes , Humanos , Masculino , Persona de Mediana Edad , Triglicéridos/sangre , Población Blanca/genéticaRESUMEN
Avasimibe, a novel inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT), is currently being developed as an antiatherosclerotic agent. The preclinical safety and toxicokinetics of the compound were assessed in beagle dogs in an escalating-dose study and in repeated-dose studies of 2-, 13-, and 52-week duration. Oral (capsule) doses up to 1000 mg/kg b.i.d. were assessed in the escalating dose study and once-a-day doses up to 300 mg/kg, 1000 mg/kg, and 1000 mg/kg were assessed in the 2-, 13-, and 52-week studies, respectively. Avasimibe was found to be a substrate and inducer of hepatic CYP 3A, producing pronounced decreases in plasma drug concentrations subsequent to Day 1. Plasma drug concentrations plateaued markedly at doses above 100 mg/kg. Significant toxicologic findings were restricted to the higher doses (> or =300 mg/kg) and included emesis, fecal consistency changes, salivation, body weight loss, microscopic and clinical pathologic evidence of hepatic toxicity, and red blood cell (RBC) morphology changes. Mortality occurred at 1000 mg/kg due to hepatic toxicity. Toxicity was more closely associated with the exaggerated pharmacodynamic effects of the compound (e.g., marked serum cholesterol decreases) seen at the high doses of avasimibe used in these studies rather than with measures of systemic exposure (Cmax or AUC). Adrenal effects were noted only in the 52-week study and consisted of minimal to mild cortical cytoplasmic vacuolization and fibrosis at doses > or =300 mg/kg, with no change in adrenal weight. In conclusion, avasimibe is an ACAT inhibitor that has minimal adrenal effects in dogs, with dose-limiting toxicity defined by readily monitored and reversible changes in hepatic function.
Asunto(s)
Acetatos/toxicidad , Glándulas Suprarrenales/efectos de los fármacos , Inhibidores Enzimáticos/toxicidad , Hipolipemiantes/toxicidad , Esterol O-Aciltransferasa/antagonistas & inhibidores , Ácidos Sulfónicos/toxicidad , Acetamidas , Acetatos/administración & dosificación , Acetatos/farmacocinética , Administración Oral , Glándulas Suprarrenales/patología , Alanina Transaminasa/sangre , Animales , Área Bajo la Curva , Arteriosclerosis/prevención & control , Colesterol/sangre , Sistema Enzimático del Citocromo P-450/metabolismo , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacocinética , Eritrocitos/efectos de los fármacos , Eritrocitos/patología , Femenino , Hipolipemiantes/administración & dosificación , Hipolipemiantes/farmacocinética , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Longevidad/efectos de los fármacos , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Sulfonamidas , Ácidos Sulfónicos/administración & dosificación , Ácidos Sulfónicos/farmacocinética , Pruebas de ToxicidadRESUMEN
Methylprednisolone (MP) pharmacokinetics and its directly suppressive effects on cortisol secretion and cell trafficking were compared in 6 chronic renal failure (CRF) subjects and 6 healthy controls. After IV administration of MP 0.6 mg/kg as Solu-Medrol, the pharmacokinetics of methylprednisolone were similar. The clearance was about 280 ml/hr/kg, volume of distribution was 1.1 l/kg, t1/2 was 2.7 hr, and fraction unbound was 0.2. Physiologic pharmacodynamics models were applied for the suppression of cortisol secretion and recirculation of basophils, T-helper cells, and T-suppressor cells. The net response (area under the curve) and inhibitory concentrations (IC50) of methylprednisolone for each pharmacodynamic parameter were similar in both groups. As the pharmacokinetics of other corticosteroids are altered in CRF, the lack of pharmacokinetic/dynamic changes of methylprednisolone may offer a therapeutic advantage for CRF patients.
Asunto(s)
Fallo Renal Crónico/metabolismo , Metilprednisolona/farmacología , Metilprednisolona/farmacocinética , Adulto , Basófilos/efectos de los fármacos , Humanos , Hidrocortisona/sangre , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Diálisis Renal , Linfocitos T Colaboradores-Inductores/efectos de los fármacos , Linfocitos T Reguladores/efectos de los fármacosRESUMEN
The circadian pattern of the immune system correlates with that of circulating T-helper cells and inversely with cortisol concentrations. Corticosteroids, both endogenous and exogenous, cause lymphocyte dimunition in blood by retention of cells in the lymphatic circulation. A physiologic pharmacodynamic model was developed to describe changes in circulating lymphocytes as a function of both endogenous cortisol and methylprednisolone concentrations. The model was applied to T-helper and T-suppressor cell data collected from six asthmatic men during baseline, after single-dose, and after 6 days of 20 mg daily methylprednisolone. The model described all phases of the study well. Baseline circadian rhythm of lymphocytes was related to cortisol concentrations. Multiple-dosing of methylprednisolone caused apparent tolerance and decreased the sensitivity of lymphocytes to corticosteroids by 116% and markedly reduced endogenous cortisol concentrations. A 60% increase in circulating T-helper cells was observed which could be accounted for by dual changes in receptor sensitivity and endogenous cortisol.
Asunto(s)
Corticoesteroides/farmacología , Corticoesteroides/fisiología , Linfocitos/efectos de los fármacos , Linfocitos/fisiología , Adulto , Asma/sangre , Relación CD4-CD8 , Ritmo Circadiano/fisiología , Glucocorticoides/farmacología , Humanos , Hidrocortisona/farmacología , Recuento de Linfocitos/efectos de los fármacos , Masculino , Metilprednisolona/farmacología , Modelos Biológicos , Linfocitos T Colaboradores-Inductores/efectos de los fármacos , Linfocitos T Colaboradores-Inductores/fisiologíaRESUMEN
OBJECTIVE: To report a pharmacodynamic model that describes increases in cortisol concentrations during administration of an adrenocorticotropin (ACTH) infusion, taking into account both steroid secretion and elimination. DATA SOURCES: Previously published data. DATA SYNTHESIS: Using a population estimate of the elimination rate constant for cortisol and equations describing changes in cortisol concentration versus time, a value for the rate of cortisol secretion (Rcort) was derived. The Rcort value more directly represents the capacity for adrenal secretion of cortisol. CONCLUSIONS: Pharmacodynamic modeling techniques were used to successfully describe the rate of cortisol secretion during an ACTH infusion. This model can be applied to assess the extent of adrenal suppression after long-term corticosteroid therapy or in the presence of disease states.
Asunto(s)
Hormona Adrenocorticotrópica , Hidrocortisona/sangre , Modelos Biológicos , Glándulas Suprarrenales/metabolismo , Semivida , Humanos , Hidrocortisona/metabolismo , Infusiones Intravenosas , Tasa de Depuración MetabólicaRESUMEN
The pharmacokinetics and selected pharmacodynamic responses to methylprednisolone were investigated in six men and six premenopausal women after a dose of 0.6 mg/kg ideal body weight. Women (luteal phase) exhibited a greater methylprednisolone clearance (0.45 versus 0.29 L/hr/kg) and shorter elimination half-life (1.7 versus 2.6 hours) than men. The volume of distribution of methylprednisolone was similar when normalized for ideal body weight. Pharmacodynamic models were used to examine the methylprednisolone suppressive effects on cortisol secretion and basophil and helper T lymphocyte trafficking. A significantly smaller 50% inhibitory concentration (IC50) value (0.1 versus 1.7 ng/ml) was seen in the women for suppression of cortisol secretion, indicating increased sensitivity. However, the area under the concentration-time curve of effect was similar for both groups. The IC50 values for effects of methylprednisolone on basophil trafficking related to estradiol concentrations in a log-linear fashion in women, with increased sensitivity found at higher estradiol concentrations. Men displayed a greater 24-hour net suppression in blood basophil numbers, but no difference was observed in net cortisol and helper T lymphocyte suppression between the sexes. These findings suggest that methylprednisolone dosages should be based on ideal body weight. Although women are more sensitive to methylprednisolone as measured by cortisol suppression, they eliminate the drug more quickly, generally producing a similar net response.
Asunto(s)
Metilprednisolona/farmacología , Caracteres Sexuales , Adulto , Basófilos/efectos de los fármacos , Femenino , Semivida , Histamina/sangre , Humanos , Hidrocortisona/sangre , Recuento de Leucocitos/efectos de los fármacos , Masculino , Ciclo Menstrual/metabolismo , Metilprednisolona/sangre , Metilprednisolona/farmacocinética , Persona de Mediana Edad , Modelos Biológicos , Valores de Referencia , Linfocitos T Colaboradores-Inductores/efectos de los fármacosRESUMEN
Nine healthy male subjects received oral fluconazole 400 mg daily, ketoconazole 200 mg twice daily or no treatment for 6 days according to a randomized, cross-over design. A single 250 mg oral dose of phenytoin suspension was administered on day 5 and serum phenytoin concentrations were measured over the following 48 h. Serum testosterone concentrations were measured for 10 h after each dose of phenytoin. Ketoconazole had no significant effect on phenytoin concentrations while the mean AUC(0,48) for phenytoin was significantly higher with fluconazole (195.2 +/- 47.8 micrograms ml-1 h) than control (146.3 +/- 49.6 micrograms ml-1 h). At 48 h, the serum phenytoin concentration averaged 1.72 micrograms ml-1 under control conditions and 3.99 micrograms ml-1 with fluconazole (132% increase). AUC(0,10) for testosterone was 42% lower than control after ketoconazole administration (P less than 0.05) but increased by 33% from 55.6 +/- 9.4 ng ml-1 h (control) to 73.8 +/- 12.6 ng ml-1 h with fluconazole. AUC(0,10) values for the testosterone precursors androstenedione and 17 alpha-hydroxyprogesterone were significantly higher in the fluconazole treatment phase as were concentrations of luteinizing hormone. The mechanism and clinical significance of the increase in testosterone concentration caused by fluconazole remains to be determined.